Inti Labs develops precision fertility technology to enhance IVF outcomes for clinics and patients. Their product suite includes OPAL for egg quality assessment, Embryo46 for advanced pre-implantation genetic testing, and ora® for non-invasive endometrial receptivity testing to optimize embryo transfer timing. These validated solutions aim to increase pregnancy success rates while reducing the need for multiple treatment cycles.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In vitro fertilization (IVF) success rates are affected by the accuracy of determining the optimal window of implantation (WOI) for embryo transfer. Traditional methods, such as endometrial biopsies, are invasive and can cause patient discomfort, while mock cycles add time and cost to the IVF process.
Solution
Inti Labs provides innovative solutions to refine the fertility journey, including ORA™, a non-invasive endometrial receptivity test that uses microRNA biomarkers in blood samples to determine the optimal timing for embryo transfer. ORA™ eliminates the need for invasive biopsies and mock cycles, offering a more comfortable and efficient experience for patients. By accurately predicting the WOI, ORA™ enables clinicians to personalize embryo transfer timing, increasing the likelihood of successful implantation and pregnancy. Inti Labs is committed to improving IVF outcomes through less invasive and more accurate testing solutions, empowering patients and families to make informed decisions at every stage of the fertility process.
Target Audience
The primary target audience includes fertility clinics, IVF specialists, and patients undergoing IVF treatment, particularly those with a history of implantation failure, limited availability of high-quality embryos, BMI variations, advanced maternal age (35+), or low AMH levels.
Features
- Non-invasive endometrial receptivity test using microRNA biomarkers in blood samples
- Predictive accuracy of over 95% in determining the window of implantation
- Streamlined workflow with same-day blood sample collection and storage service (ORA™ Reserve)
- Personalized Embryo Transfer (pET) Calculator to determine the optimal time for embryo transfer based on ORA™ results
- Eliminates the need for invasive endometrial biopsies and mock cycles
- Designed to support fertility specialists in caring for their patients